Adipex and Phentermine Doctors in Philadelphia, Brooklyn and NYC
Phentermine can be a useful, affordable appetite suppressant for carefully selected patients—but it is no longer the only medical weight-loss option. W8MD physicians with more than 20 years of clinical experience help patients compare phentermine, phentermine/topiramate, Wegovy, Zepbound, oral GLP-1 medications, other prescription pills, nutrition, sleep care and long-term maintenance.
- Phentermine and Adipex evaluation
- Phentermine/topiramate and Qsymia
- Wegovy and semaglutide options
- Zepbound and tirzepatide options
- New oral GLP-1 weight loss pills
- Maintenance and weight-regain prevention
What Are Adipex and Phentermine?
Adipex-P is a brand of phentermine, a prescription sympathomimetic appetite suppressant. Its FDA labeling describes it as a short-term adjunct to calorie reduction, exercise and behavior modification for selected adults with obesity, or overweight with qualifying risk factors.
Phentermine may reduce hunger and make a calorie deficit easier to follow. It does not directly “melt” fat, replace nutrition or guarantee continued weight loss. Response varies, and tolerance, side effects or returning hunger may limit long-term usefulness.
- Usually taken in the morning to reduce insomnia risk
- Available in several tablet and capsule strengths
- Generally less expensive than brand-name GLP-1 treatment
- Requires blood-pressure and cardiovascular review
- May cause dry mouth, constipation, restlessness or insomnia
- Can increase heart rate or blood pressure
- Is a controlled substance and is not appropriate for everyone
Who May Not Be a Good Candidate for Phentermine?
A clinician must review the full history. The following are examples rather than a complete list of contraindications and precautions.
Cardiovascular Disease
Phentermine is generally avoided with coronary disease, stroke, arrhythmias, heart failure or uncontrolled hypertension.
Blood Pressure or Fast Heart Rate
Even controlled hypertension requires careful review and monitoring because stimulant effects may worsen pressure or pulse.
Pregnancy and Breastfeeding
Weight-loss medications should not be used during pregnancy. Qsymia has additional fetal-risk precautions and requires effective pregnancy prevention.
MAO Inhibitors and Other Drugs
Phentermine must not be used during or within 14 days after an MAO inhibitor. Other stimulants and interacting medicines must be reviewed.
Hyperthyroidism or Glaucoma
These conditions can make sympathomimetic appetite suppressants unsafe or inappropriate.
Insomnia, Agitation or Substance History
Stimulant effects, anxiety, sleep disruption and misuse risk require careful clinical judgment.
Phentermine/Topiramate Compared With GLP-1 Weight Loss Injections
These figures come from different trials with different participants, durations, doses and methods. They provide context but are not a direct promise or a head-to-head comparison.
Qsymia
Phentermine/topiramate ERAverage weight loss at 56 weeks in the CONQUER study for the recommended and top doses, compared with 1.2% for placebo.
Wegovy
Semaglutide 2.4 mgMean weight loss at 68 weeks in STEP 1, compared with 2.4% for placebo, with reduced-calorie nutrition and physical activity.
Zepbound
TirzepatideMean weight loss at 72 weeks in SURMOUNT-1 across 5 mg, 10 mg and 15 mg doses, compared with 3.1% for placebo.
Foundayo
Oral orforglipronFDA-approved in 2026 for eligible adults who prefer a daily pill. Results and tolerability vary by dose and diabetes status.
Qsymia Versus Wegovy and Zepbound
- Administration: Qsymia is a daily capsule; Wegovy and Zepbound are usually weekly injections.
- Average trial loss: newer incretin injections generally produced greater mean weight loss than phentermine/topiramate in separate pivotal trials.
- Cost: generic or traditional oral pathways may be less expensive than branded GLP-1 medication.
- Pregnancy: all weight-loss medications are inappropriate during pregnancy; Qsymia has particular fetal oral-cleft risk and pregnancy-testing requirements.
- Cardiovascular effects: Qsymia can increase heart rate, and its effect on cardiovascular morbidity and mortality has not been established.
- Additional indications: Wegovy has specific cardiovascular-risk and MASH indications; Zepbound has a specific obesity-related OSA indication.
- Side effects: Qsymia may cause tingling, cognitive or mood effects, dry mouth and insomnia; GLP-1 medicines commonly cause gastrointestinal symptoms.
- Stopping: high-dose Qsymia must be tapered; stopping GLP-1 treatment may lead to returning hunger and weight regain.
Other Weight Loss Medications W8MD Can Help You Compare
| Option | Status and type | How taken | Potential advantages | Important considerations |
|---|---|---|---|---|
| Phentermine / Adipex-P | Short-term label Sympathomimetic appetite suppressant |
Daily tablet or capsule | Established, generally lower cost and may reduce hunger quickly | Controlled substance; cardiovascular, blood-pressure, sleep, anxiety and interaction review |
| Qsymia | FDA approved Phentermine/topiramate ER |
Daily capsule | Long-term oral option with greater average trial loss than phentermine alone | Pregnancy prevention, cognitive or mood effects, tingling, heart rate, glaucoma, kidney stones and tapering |
| Wegovy injection | FDA approved Semaglutide GLP-1 |
Weekly injection | Substantial average weight loss; product-specific cardiovascular and injectable MASH indications | Gastrointestinal, gallbladder and pancreatitis precautions; pregnancy and thyroid-related contraindications |
| Wegovy tablets | Recently approved Oral semaglutide |
Daily tablet with specific administration instructions | Needle-free semaglutide option for eligible adults | Timing, food, water, interactions, escalation and the same major GLP-1 precautions |
| Wegovy HD 7.2 mg | Approved 2026 Higher-dose semaglutide |
Weekly injection after lower-dose treatment | Additional option for selected adults needing more weight reduction | Not a starting dose; gastrointestinal and tolerability monitoring |
| Zepbound | FDA approved Tirzepatide dual GIP/GLP-1 |
Weekly injection | Among the greatest average weight loss in pivotal obesity trials; specific OSA indication | Gastrointestinal, gallbladder, pancreatitis, pregnancy, thyroid and oral-contraceptive considerations |
| Foundayo | Approved 2026 Oral orforglipron GLP-1 |
Daily tablet | Needle-free oral GLP-1 option without peptide-style fasting administration requirements | Escalation, gastrointestinal effects, drug interactions, pregnancy and thyroid-related contraindications |
| Saxenda | FDA approved Liraglutide GLP-1 |
Daily injection | Established GLP-1 option for adults and selected adolescents | Daily dosing and GLP-1 class precautions |
| Contrave | FDA approved Naltrexone/bupropion ER |
Daily tablets with escalation | May help selected patients with appetite, cravings and reward-related eating | Opioid use, seizures, uncontrolled hypertension, eating disorders and psychiatric or interaction review |
| Orlistat | FDA approved Fat-absorption inhibitor |
With fat-containing meals | Nonstimulant and non-GLP-1 pathway; over-the-counter form available | Gastrointestinal effects, fat-soluble vitamins and drug interactions |
How W8MD Helps You Choose the Right Option
The medication with the largest average trial result is not always the best individual treatment. W8MD physicians balance safety, benefit, preference, insurance and the ability to continue treatment.
Review Your Medical History
Cardiovascular disease, blood pressure, glaucoma, thyroid disease, kidney stones, seizures, mood, pregnancy and other factors may change the safest choice.
Check Drug Interactions
W8MD reviews current prescriptions, stimulants, opioids, MAO inhibitors, diabetes medicines and other therapies.
Match Treatment to Goals
A patient seeking modest appetite control may need a different plan from someone needing 15% or more loss for major health complications.
Compare Cost and Coverage
W8MD can compare traditional low-cost pills, covered brand medication, prior authorization and affordable self-pay options.
Build the Food Plan
Medication works best with adequate protein, vegetables, fluids, fiber and a sustainable calorie deficit rather than severe under-eating.
Evaluate Sleep Apnea
Snoring, fatigue and untreated OSA can undermine weight control and cardiometabolic health. W8MD offers integrated sleep evaluation.
Monitor Safety and Response
Follow-up may include weight, waist, blood pressure, pulse, sleep, appetite, adverse effects and clinically indicated laboratory testing.
Change Course When Needed
If response is inadequate or side effects occur, W8MD can adjust the plan rather than continuing an ineffective medication indefinitely.
Plan for Maintenance Early
Maintenance is discussed before goal weight so the patient has a strategy for appetite, medication, nutrition and early regain.
Medical Support, Medication, Nutrition and Maintenance
More W8MD Weight Loss Success Stories
These stories come from W8MD’s published testimonials and describe individual experiences. They do not prove that one medication caused the result and do not guarantee similar weight loss or medical outcomes.
D.M. described the program as “truly a life changer,” initially reported losing 87 pounds in ten months and later reported approximately 100 pounds lost with long-term maintenance.D.M. — Published W8MD story
Dawn V. reported losing approximately 150 pounds and emphasized physician guidance, accountability, encouragement and following a medically grounded plan.Dawn V. — Published W8MD story
W8MD published the experience of a patient who had struggled with obesity for years and reported losing more than 100 pounds using a comprehensive program involving diet, activity and behavioral support.Published W8MD success story
Tom G. reported losing 75 pounds, increased energy and improved mobility while receiving weight-management and sleep-related care.Tom G. — Published Philadelphia story
Joane reported losing 60 pounds over seven months and said she received guidance from the physician and staff throughout the process.Joane — Published patient review
A mother reported that her daughter lost 58 pounds while she lost 25 pounds. She described improved confidence for her daughter and helpful access to W8MD staff.Published W8MD family story
Published patient-review screenshot
Published success-story screenshot
Published testimonial screenshot
How W8MD Helps Patients Keep the Weight Off
Hunger and weight may return after medication is stopped or structure is relaxed. W8MD treats maintenance as an active phase of chronic weight management rather than a brief instruction to “try harder.”
Maintenance Medication Review
Continue, adjust, change or taper treatment only after reviewing benefits, risks, appetite, cost and regain risk.
Early Regain Threshold
Agree on a small weight or waist increase that triggers action before most of the lost weight returns.
Protein and Strength
Support lean mass with adequate protein and resistance activity when medically appropriate.
Hunger and Craving Monitoring
Watch for increasing food noise, portions, nighttime eating and loss of satiety.
Sustainable Meal Structure
Transition from a loss-phase plan to a realistic long-term pattern without returning to previous portions and habits.
Sleep and OSA Care
Continue sleep-apnea treatment and address sleep loss that can worsen appetite and fatigue.
Plateau and Relapse Planning
Use planned adjustments rather than abandoning the program when progress slows or life becomes difficult.
Long-Term Follow-Up
Periodic physician review supports safety, accountability and adaptation as health, medications and insurance change.
W8MD GLP-1 Starting Options
Some patients use phentermine or Qsymia because they are clinically appropriate and affordable. Others may prefer a GLP-1 option. W8MD can compare both pathways.
Semaglutide-Based Programs
$29.99+Published weekly starting-dose pricing for certain eligible patients using insurance for qualifying medical visits.
Published self-pay options begin at $59.99+ per week.
Tirzepatide-Based Programs
$45.00+Published weekly starting-dose pricing for certain eligible patients using insurance for qualifying medical visits.
Published self-pay options begin at $69.99+ per week.
“Insurance for visits” does not mean the medication is covered by the pharmacy benefit. Starting prices apply to qualifying programs and starting doses and may refer to compounded prescription medication when legally available and clinically appropriate. Compounded medications are not FDA-approved and are not the same as Wegovy or Zepbound. Total cost varies by dose, pharmacy, medication source, shipping, visits, laboratory needs, copay, deductible, coinsurance and other charges.
W8MD Phentermine and Medical Weight Loss Locations
Brooklyn, New York City
Northeast Philadelphia
1718 Welsh Road
2nd Floor, Suite C
Philadelphia, PA 19115 215-676-2334
Ask W8MD Which Weight Loss Option May Be Right for You
Use the form to ask about phentermine, Qsymia, Wegovy, Zepbound, oral GLP-1 medications, insurance, affordable self-pay programs, nutrition, sleep apnea or maintenance care. Submission is a request and does not confirm an appointment.
Do not submit urgent symptoms or highly sensitive medical information through a general website form. An appointment is not confirmed until W8MD staff contact you. Call 911 or seek emergency care for a medical emergency.
Phentermine, Qsymia and GLP-1 Weight Loss FAQ
Does W8MD prescribe Adipex or phentermine?
A W8MD physician may prescribe phentermine when it is medically appropriate after reviewing blood pressure, cardiovascular history, current medications, contraindications and treatment goals. A consultation does not guarantee a prescription.
Is phentermine the best first weight loss medication?
Not necessarily. Phentermine can be affordable and effective for selected patients, but another oral medication, a GLP-1 treatment or a nonmedication plan may be safer, more effective or easier to maintain.
How does Qsymia compare with Wegovy?
In separate pivotal trials, phentermine/topiramate produced approximately 7.8%–9.8% mean loss at 56 weeks, while semaglutide 2.4 mg produced 14.9% at 68 weeks. These were not head-to-head trials and individual results vary.
How does Qsymia compare with Zepbound?
In separate trials, Qsymia produced approximately 7.8%–9.8% mean loss at 56 weeks, while tirzepatide produced 15.0%–20.9% at 72 weeks depending on dose. Cost, contraindications, side effects and preference may still make Qsymia appropriate for some patients.
Can phentermine/topiramate be used long term?
Qsymia is FDA-approved for chronic weight management with reduced-calorie nutrition and physical activity. It requires response assessment, pregnancy precautions and gradual discontinuation from the highest dose.
What recently approved weight loss medications are available?
Recent options include daily Wegovy tablets, higher-dose Wegovy 7.2 mg injection for selected adults and Foundayo oral orforglipron. Availability, insurance and suitability vary.
Can W8MD help with Wegovy or Zepbound prior authorization?
W8MD may submit prior-authorization documentation when the plan includes medication coverage and the patient meets its requirements. The insurer makes the final decision.
What happens when I reach my goal weight?
W8MD can create a maintenance plan involving medication reassessment, nutrition, protein, strength activity, sleep care, a maintenance range and early action if appetite or weight begins to rise.
Will I regain weight after stopping phentermine or a GLP-1?
Hunger and weight may return after medication is stopped. The degree varies. Stopping or tapering should be planned with a clinician, and maintenance habits and follow-up should begin before treatment ends.
Does W8MD offer sleep-apnea care?
Yes. W8MD can screen for obstructive sleep apnea, arrange home testing when appropriate and support treatment. Zepbound has a specific indication for moderate-to-severe OSA in eligible adults with obesity.
Does W8MD accept insurance?
W8MD accepts many insurance plans for qualifying medical visits. Medication coverage is separate. Self-pay and lower-cost prescription options may be discussed when drug coverage is unavailable.
Are the W8MD success stories typical?
No specific result is guaranteed. Testimonials reflect individual patients with different starting weights, treatment plans, medical conditions and levels of adherence.
Medication Comparison Resources
Choose a Weight Loss Plan You Can Safely Continue—and Maintain
Speak with W8MD physicians with more than 20 years of experience about phentermine, Qsymia, Wegovy, Zepbound, oral GLP-1 medications, nutrition, sleep apnea and a personalized plan for keeping the weight off.